Regencell Bioscience (NASDAQ:RGC) Shares Gap Down – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $16.00, but opened at $15.01. Regencell Bioscience shares last traded at $15.34, with a volume of 72,857 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Regencell Bioscience Trading Up 2.5%

The firm’s 50-day moving average price is $14.98.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RGC. Greenfield Savings Bank bought a new stake in shares of Regencell Bioscience during the second quarter valued at approximately $187,000. Y Intercept Hong Kong Ltd bought a new position in Regencell Bioscience in the second quarter worth $222,000. XTX Topco Ltd purchased a new position in Regencell Bioscience during the third quarter valued at $598,000. BNP Paribas Financial Markets purchased a new position in Regencell Bioscience during the second quarter valued at $768,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Regencell Bioscience during the 2nd quarter valued at $1,701,000. Institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.